After monitoring 144 participants for a median of 36 months, it turned out that the men taking metformin didn’t fare any better than those on a placebo. Yep, you read that right. No significant difference in progression rates.
Men taking metformin showed no better outcomes than those on placebo after 36 months. Disappointing, to say the least.
It’s almost like metformin was just along for the ride. This raises eyebrows, especially since many had high hopes for the drug to do something—anything!—to help slow down cancer. However, ongoing excitement in the oncology community regarding metformin’s potential in cancer treatment suggests that research is still evolving.
But wait, there’s more. Other studies have shown that metformin has some effects in castration-resistant prostate cancer (CRPC), with a few patients showing PSA declines. Some even experienced disease stabilization.
However, the overall clinical benefits? Limited. It seems like metformin is not the magical cure-all some hoped for.
The drug has also been tested in the context of metabolic syndrome in prostate cancer patients, but again, no significant improvements.
Just more disappointing results. And if you’re looking for a silver lining, it’s hard to find one here.
